Portal de Periódicos da CAPES

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: efficacy by baseline body surface area (BSA) involvement and baseline Psoriasis Area and Severity Index (PASI)

2023; Volume: 7; Issue: 2 Linguagem: Inglês

10.25251/skin.7.supp.120

2574-1624

April W. Armstrong, Mark Lebwohl, Jerry Bagel, Todd Schlesinger, Subhashis Banerjee, Renata M. Kisa, Thomas Scharnitz, Kim Hoyt, Bruce Strober,

Cytokine Signaling Pathways and Interactions